BioNTech’s Pipeline Progress and Insider Sale Set the Stage for a High-Stakes Earnings Report

BioNTech advances BNT116 lung cancer trial with promising data, but an insider stock sale and looming earnings report fuel investor uncertainty over its pivot from COVID-19 vaccines.

The coming weeks will test whether BioNTech can convince investors that its oncology pivot is gaining enough traction to offset a steep decline in COVID-19 vaccine revenue. The Mainz-based biotech has opened a new patient cohort in its BNT116 lung cancer trial, while a recent insider stock sale and a looming earnings report are adding to the tension.

Since April 27, the company has been enrolling patients with advanced non-small cell lung cancer (NSCLC) who carry a RET alteration into the so-called RET cohort of its LuCa-MERIT-1 study. The mRNA-based vaccine, which targets six tumor-associated antigens commonly expressed in lung cancer, is being tested in combination with RET inhibitors at several U.S. sites, including the MD Anderson Cancer Center. The goal is to exploit synergistic effects between mRNA-induced immune activation and targeted molecular therapy.

The expansion follows encouraging interim data from other arms of the trial. In a 20-patient cohort that received BNT116 alongside docetaxel, the objective response rate hit 35 percent and the disease control rate reached 85 percent. Even stronger results came from a combination with the PD-1 inhibitor cemiplimab in patients who had previously stopped responding to PD-1 therapy. That group posted a confirmed response rate of 45 percent and a median progression-free survival of 9.9 months, prompting the company to advance the combination into Phase 2.

Insider Sale Raises Eyebrows

Just ahead of these developments, Chief Operating Officer Sierk Poetting indirectly sold 50,000 shares at an average price of roughly $110, netting about $5.5 million. The sale was executed through a pre-arranged trading plan, but its proximity to the upcoming first-quarter earnings report on May 5 has caught the attention of market watchers. Poetting still holds nearly 400,000 shares in the company.

BioNTech’s stock currently trades at around €86, having lost roughly 8 percent over the past week despite a solid 16 percent gain in the prior month. The volatility reflects a broader uncertainty about the company’s transition from a pandemic-era powerhouse to a pure-play oncology firm.

Analyst Views Diverge

Wall Street remains broadly optimistic, though not uniformly so. H.C. Wainwright and Bank of America Securities both maintain price targets of $130, with BofA pointing to positive data on the antibody-drug conjugate trastuzumab pamirtecan. Morgan Stanley recently nudged its fair value estimate up to $126. But Leerink Partners is more cautious, cutting its target to $94 amid concerns about the CTLA-4 inhibitor gotistobart following Phase 3 observations. BMO Capital flags leadership transition risks, while TD Cowen stresses that COVID revenues remain a critical factor in the company’s valuation.

A Well-Funded Transition

BioNTech enters this pivotal period with a formidable cash position of €17.2 billion, providing ample runway for its oncology ambitions. The company aims to have at least 15 ongoing Phase 3 studies across various cancer indications by the end of 2026 and to secure ten oncology approvals by 2030. This year alone, it plans to launch six new Phase 3 oncology trials.

The first major checkpoint comes on May 5, when BioNTech reports first-quarter results. Revenue is expected to fall to roughly €2 billion for the full year 2026 after a billion-euro loss in 2025. The company will also hold its virtual annual general meeting on May 15, where shareholders will vote on expanding the supervisory board and carrying forward the entire net profit to new accounts.

The earnings call and shareholder meeting will give management a chance to demonstrate that the pipeline progress can eventually bridge the revenue gap left by the fading COVID franchise. For now, the market is watching closely — and the mixed signals from insider trading, analyst downgrades, and promising early-stage data are keeping everyone on edge.